GovWire

Research: Valproate: Paternal exposure to valproate and risk of neurodevelopmental disorders and congenital malformations in offspring

Medicines Healthcare Products Regulatory Agency

September 5
13:32 2024

This report presents the review of the results of a study on the potential risk to children born to men who took valproate in the 3 months before conception, and the steps that the MHRA are taking to implement new safety measures in consultation with the clinical community and other stakeholders.

Updates to this page

Published 5 September 2024

Sign up for emails or print this page